respiratory infection News
-
BreathSpec and the fight against AMR
The Imspex Group’s BreathSpec technology is well-placed to play a leading role in combatting antimicrobial resistance by helping healthcare practitioners to differentiate between bacterial and viral causes of respiratory infection. This would better allow the right antibiotic to be prescribed to the right patient at the right time and in the right dose , thereby helping to minimise ...
-
Breath analysis to detect COVID-19
Efforts to develop a quick and non-invasive breath test for the presence of COVID-19 are underway in Vancouver, British Columbia. Imspex’s BreathSpec® is one of a battery of tests that are being used by Dr Renelle Myers and her Vancouver Coastal Health team in their work to develop a breath test that identifies the possible presence of COVID-19 in people who are showing minimal symptoms ...
-
Om Pharma and Astrazeneca enter into Strategic Collaboration to Expand Presence in Respiratory and Immunology Fields in China
OM Pharma enters into a strategic collaboration agreement granting AstraZeneca the exclusive right to import and distribute the immunological therapy Broncho-Vaxom® for the prevention and treatment of respiratory tract infections in China (excluding Hong Kong, Macau, and Taiwan). OM Pharma and AstraZeneca celebrated their strategic collaboration agreement today at a partnership signing ...
-
Sekisui Diagnostics Announces Launch of The Osom® Ultra Plus Flu A&B Test in Europe
High performance, point-of-care rapid test for the detection of Influenza A&B Burlington, MA – November 17, 2020 –SEKISUI Diagnostics announces it has received CE Marking (Conformité Européenne) for the OSOM® Ultra Plus Flu A&B Test and has begun marketing in Europe. The test utilizes traditional lateral flow technology with performance near or exceeding ...
-
Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine
SOUTH SAN FRANCISCO, Calif, January 10, 2020 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MV-012-968, an investigational, live attenuated vaccine for protection against respiratory syncytial virus (RSV) ...
-
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
Funding Will Support Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Respiratory Infections in CF Patients CF Foundation to Invest up to $5 Million in BiomX Common Stock Data Readouts from Phase 1b/2a CF Trial of BX004 Expected in 2022 BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel ...
By BiomX
-
Showcase
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
Fusion Genomics Receives $1 Million from CQDM To Study ONETest RTI Assay
We are pleased to share the news that Fusion Genomics has received a $1 million award to conduct a study evaluating our comprehensive, novel ONETest PathoGenome assay for the detection of pathogens associated with respiratory tract infections (RTIs). Due in great part to limitations associated with current diagnostic tests, RTIs are a leading cause of morbidity, mortality, and hospitalizations ...
-
Imspex’s patent portfolio grows
Imspex Diagnostics’ patent portfolio recently grew, with news that the European Patent Office has granted the patent “Method for measuring human exhaled air”. This is the platform that is used to screen for disease indications such as bacterial and viral respiratory tract infections, Group B Streptococcus infection, lung cancer and other chronic inflammatory respiratory ...
-
Espoo Health Services chose Genano to protect patients and staff from viruses in the air
Espoo Health Services was well prepared for the expansion of the corona epidemic and reorganized its operations. One of the tasks was to change the Samaria health station in the center of Espoo, Finland, into an infection center focusing on the treatment of respiratory infections. In the next phase, another health station was prepared for similar use in case the first infection center's ...
-
Virometix announces initiation of Phase 1 clinical trial with its V-306 vaccine candidate
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, is pleased to announce that the Belgian health authority, FAMHP, has approved the company’s clinical trial application for the first-in-human phase 1 study of its respiratory syncytial virus (RSV) ...
By Virometix AG
-
GC-IMS for medical and healthcare applications
Imspex Diagnostics’ proprietary GC-IMS analytical technology platform has built a legacy of being a versatile, accurate and robust analytical research tool in situations where compound combinations are complex and/ or concentrations are low. Much of this legacy has centred around volatile compounds in industrial and more recently environmental and food production settings. The ultra-highly ...
-
New respiratory multitest
The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or Influenza B and/or Respiratory Syncytial Virus (RSV) ...
-
Nob Hill Therapeutics to Present at Partnership Opportunities in Drug Delivery (PODD) Conference
Nob Hill Therapeutics' Executive Chairman Paul Atkins will be presenting at the Partnership Opportunities in Drug Delivery (PODD) conference during the DryNeb – Advancing Pulmonary Drug Delivery session on Friday, October 29th at 12:00pm ET. PODD is an annual virtual event where members of the pharma, biotech and drug delivery industries gather to share cutting-edge business and ...
-
Air Pollution Can Alter Effectiveness of Antibiotics
Researchers from the University of Leicester have for the first time discovered that bacteria that cause respiratory infections are directly affected by air pollution - increasing the potential for infection and changing the effectiveness of antibiotic treatment. The interdisciplinary study, which has been published in the journal Environmental Microbiology, has important implications for the ...
By Camfil Ltd
-
Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO
ALBUQUERQUE, N.M. (PRWEB) August 23, 2022 Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat lung fungal infection using an innovative first-of-its-kind dry powder nebulizer delivery platform technology. The funds will be used to develop the drug ...
-
Global Handwashing Day
Global Handwashing Day is an international campaign to promote hygiene and good sanitation. The day highlights the importance that simply washing hands with soap is the most effective and affordable way to prevent diseases and save lives. Dubbed as a “do it yourself” vaccine, the annual global advocacy day is dedicated to promoting a global/local culture of handwashing with ...
-
EPA, University of Michigan to research health effects of roadway pollution on children
The U.S. Environmental Protection Agency has announced a $1.4 million joint study with the University of Michigan on the health effects of air pollution on children living near the nation’s heavily traveled thoroughfares. The study is funded through EPA’s Science to Achieve Results program. “The knowledge gained from this study will arm local governments with the best available science when ...
-
National COPD Awareness Month Discussed in New Online Video
Today the IAQ Video Network and Cochrane & Associates announced the release of their latest educational video. Their newest production discusses National COPD Awareness Month, which takes place during the month of November. “Chronic Obstructive Pulmonary Disease (COPD) is a serious lung disease that impacts millions of Americans, and hundreds of millions worldwide, making it hard to ...
-
USMI and JCRI Research Teams Develop Treatment System for COVID and other Respiratory Infections and Diseases
US Medical Innovations, LLC (USMI) and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance in connection with JCRI-ABTS’s US National Stage Application (Serial No. 17/284,762) entitled “SYSTEM FOR TREATMENT OF RESPIRATORY INFECTIONS AND ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you